The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Updates from UK NCRI AML18
Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, discusses results from the UK NCRI AML18 trial (NCT02272478) investigating a single versus fractionated schedule of gemtuzumab ozogamicin in combination with daunorubicin/cytarabine as induction therapy in older patients with acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
